TSE:BHC - Bausch Health Companies Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: C$47.75
  • Forecasted Upside: 23.26 %
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
C$38.74
▲ +0.63 (1.65%)
1 month | 3 months | 12 months
Get New Bausch Health Companies Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for BHC and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BHC

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
C$47.75
▲ +23.26% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Bausch Health Companies in the last 3 months. The average price target is C$47.75, with a high forecast of C$51.50 and a low forecast of C$44.00. The average price target represents a 23.26% upside from the last price of C$38.74.

Buy

The current consensus among 2 investment analysts is to buy stock in Bausch Health Companies.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/22/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/21/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/19/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/17/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/16/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/16/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/15/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/14/2021

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
4/30/2021Royal Bank of CanadaReiterated RatingOutperformC$51.50
i
2/25/2021BarclaysBoost Price TargetOverweightC$44.00
i
2/18/2021Royal Bank of CanadaBoost Price TargetNAC$42.00
i
6/11/2019BarclaysLower Price TargetC$31.00 ➝ C$28.00
i
2/21/2019BMO Capital MarketsLower Price TargetC$26.00 ➝ C$25.00
i
8/8/2018Cantor FitzgeraldReiterated RatingOverweight
i
Rating by L. Chen at Cantor Fitzgerald
(Data available from 6/14/2016 forward)

Bausch Health Companies

Bausch Health Companies Inc. develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through four segments: Bausch + Lomb/International, Salix, Ortho Dermatologics, and Diversified Products. The Bausch + Lomb/International segment offers products with a focus on the vision care, surgical, and consumer and ophthalmology Rx products in the United States; and Solta products, branded and generic pharmaceutical products, OTC products, and medical device products, and Bausch + Lomb products in Canada, Europe, Asia, Australia, Latin America, Africa, and the Middle East. The Salix segment provides gastroenterology products in the United States. The Ortho Dermatologics segment offers dermatological products in the United States; and Solta medical aesthetic devices internationally. The Diversified Products segment provides pharmaceutical products in the areas of neurology and other therapeutic classes, as well as generic and dentistry products in the United States. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.
Read More

Today's Range

Now: C$38.74
C$38.18
C$38.75

50 Day Range

MA: C$37.31
C$33.19
C$40.11

52 Week Range

Now: C$38.74
C$19.88
C$43.97

Volume

342,833 shs

Average Volume

628,175 shs

Market Capitalization

C$13.88 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Bausch Health Companies?

The following Wall Street analysts have issued stock ratings on Bausch Health Companies in the last twelve months: Barclays PLC, and Royal Bank of Canada.
View the latest analyst ratings for BHC.

What is the current price target for Bausch Health Companies?

2 Wall Street analysts have set twelve-month price targets for Bausch Health Companies in the last year. Their average twelve-month price target is C$47.75, suggesting a possible upside of 23.3%. Royal Bank of Canada has the highest price target set, predicting BHC will reach C$51.50 in the next twelve months. Barclays PLC has the lowest price target set, forecasting a price of C$44.00 for Bausch Health Companies in the next year.
View the latest price targets for BHC.

What is the current consensus analyst rating for Bausch Health Companies?

Bausch Health Companies currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe BHC will outperform the market and that investors should add to their positions of Bausch Health Companies.
View the latest ratings for BHC.

What other companies compete with Bausch Health Companies?

How do I contact Bausch Health Companies' investor relations team?

The company's listed phone number is 514-744-6792. The official website for Bausch Health Companies is www.valeant.com.